Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Merck Gains Ahead Of Organon Listing Following Hexavalent Vaccine Launch

Published 03/06/2021, 15:06
Updated 03/06/2021, 15:06
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing – Merck (NYSE:MRK) shares rose 1% Thursday ahead of the day’s listing of Organon (NYSE:OGN_w), its spun-off business that has a broad portfolio of medicines and products.

The spinoff is expected to net Merck incremental operating efficiencies of approximately $1.5 billion over three years, with approximately $500 million realized during 2021. In connection with the spinoff, Merck received approximately $9 billion of Organon.

The announcement of the spin-off is one of the several positive developments that have happened at the German company this month.

The completion of the spin-off follows three announcements on Tuesday, only one of which was made by Merck.

The first was the launch of VAXELIS, the only hexavalent (six-in-one) combination vaccine in the U.S. indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to haemophilus influenzae type b.

VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

The novel vaccine has been developed as part of a U.S.-based partnership between Merck and Sanofi (PA:SASY) Pasteur (NASDAQ:SNY).

In Tuesday’s second announcement, biotechnology company Immutep (NASDAQ:IMMP) announced it will collaborate with Merck in the safety trial of an immunotherapy treatment the Sydney, Australia-based company is developing for cancer.

The trial will be done in combination with another immunotherapy that Merck and GlaxoSmithKline (NYSE:GSK) are jointly developing.

Tuesday’s third disclosure involving Merck was California-based Sutro Biopharma (NASDAQ:STRO) saying it has received a milestone payment from Merck for patient enrollment to study next-generation cancer and autoimmune therapeutics.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.